[go: up one dir, main page]

PE20080539A1 - MACROCYCLIC PYRIDAZINONYLS AS SERINE PROTEASE INHIBITORS OF HEPATITIS C - Google Patents

MACROCYCLIC PYRIDAZINONYLS AS SERINE PROTEASE INHIBITORS OF HEPATITIS C

Info

Publication number
PE20080539A1
PE20080539A1 PE2007001036A PE2007001036A PE20080539A1 PE 20080539 A1 PE20080539 A1 PE 20080539A1 PE 2007001036 A PE2007001036 A PE 2007001036A PE 2007001036 A PE2007001036 A PE 2007001036A PE 20080539 A1 PE20080539 A1 PE 20080539A1
Authority
PE
Peru
Prior art keywords
aryl
substituted
hepatitis
serine protease
pyridazinonyls
Prior art date
Application number
PE2007001036A
Other languages
Spanish (es)
Inventor
Joel D Moore
Datong Tang
Yat Sun Or
Zhe Wang
Original Assignee
Enanta Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/832,893 external-priority patent/US7718612B2/en
Application filed by Enanta Pharm Inc filed Critical Enanta Pharm Inc
Publication of PE20080539A1 publication Critical patent/PE20080539A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE A ES -(C=O)-O-R1, -(C=O)-R2, S(O)2-R1, ENTRE OTROS; R1 ES ARILO SUSTITUIDO O NO, HETEROARILO SUSTITUIDO O NO, HETEROCICLOALQUILO, CICLOALQUILO C1-C8, ENTRE OTROS; R2 ES H, ARILO SUSTITUIDO O NO, HETEROCICLOALQUILO SUSTITUIDO, -ALQUENILO C2-C8, ENTRE OTROS; G ES -NHS(O)2-R3 Y -NH(SO2)NR4R5; R3 ES ARILO SUSTITUIDO O NO, HETEROARILO, ALQUILO C1-C8, -CICLOALQUENILO -C3-C12, ENTRE OTROS; R4 Y R5 SON CADA UNO H, ARILO, HETEROARILO, HETEROCICLOALQUILO, ENTRE OTROS; L ES -CH2-, -O-, -S- Y S(O)2-; X, Y y Z SON CADA UNO H, -CN, -N3, HALOGENO, ARILO, ENTRE OTROS; ----DENOTA UN ENLACE CARBONO-CARBONO SIMPLE O DOBLE; j ES 0-4; k ES 1-3; m ES 0-2; n ES 1-3. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ACTIVIDAD SERINA PROTEASA, PARTICULARMENTE NS3-NS4A PROTEASA DEL VIRUS DE LA HEPATITIS C (VHC)REFERS TO A COMPOUND OF FORMULA I, WHERE A IS - (C = O) -O-R1, - (C = O) -R2, S (O) 2-R1, AMONG OTHERS; R1 IS ARYL, SUBSTITUTED OR NOT, HETEROARYL, SUBSTITUTED OR NOT, HETEROCICLOALKYL, CYCLOALKYL C1-C8, AMONG OTHERS; R2 IS H, ARYL SUBSTITUTED OR NOT, HETEROCYCLALKYL SUBSTITUTED, -ALKENYL C2-C8, AMONG OTHERS; G IS -NHS (O) 2-R3 AND -NH (SO2) NR4R5; R3 IS ARYL, SUBSTITUTED OR NOT, HETEROARYL, C1-C8 ALKYL, -CYCLOALKENYL -C3-C12, AMONG OTHERS; R4 AND R5 ARE EACH H, ARYL, HETEROARYL, HETEROCICLOALKYL, AMONG OTHERS; L IS -CH2-, -O-, -S- AND S (O) 2-; X, Y and Z ARE EACH H, -CN, -N3, HALOGEN, ARYL, AMONG OTHERS; ---- DENOTES A SIMPLE OR DOUBLE CARBON-CARBON LINK; j IS 0-4; k IS 1-3; m IS 0-2; n IS 1-3. ALSO REFERRED TO A PHARMACEUTICAL COMPOSITION. SAID COMPOUNDS ARE INHIBITORS OF SERINE PROTEASE ACTIVITY, PARTICULARLY NS3-NS4A PROTEASE OF THE HEPATITIS C VIRUS (HCV)

PE2007001036A 2006-08-04 2007-08-06 MACROCYCLIC PYRIDAZINONYLS AS SERINE PROTEASE INHIBITORS OF HEPATITIS C PE20080539A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49984406A 2006-08-04 2006-08-04
US11/832,893 US7718612B2 (en) 2007-08-02 2007-08-02 Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors

Publications (1)

Publication Number Publication Date
PE20080539A1 true PE20080539A1 (en) 2008-05-16

Family

ID=39033583

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001036A PE20080539A1 (en) 2006-08-04 2007-08-06 MACROCYCLIC PYRIDAZINONYLS AS SERINE PROTEASE INHIBITORS OF HEPATITIS C

Country Status (4)

Country Link
CO (1) CO6020004A1 (en)
EC (1) ECSP077649A (en)
PE (1) PE20080539A1 (en)
WO (1) WO2008019303A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
AR057456A1 (en) 2005-07-20 2007-12-05 Merck & Co Inc HCV PROTEASA NS3 INHIBITORS
CN101415705B (en) 2005-10-11 2011-10-26 因特蒙公司 Compounds and methods for inhibiting hepatitis c viral replication
KR20090024834A (en) 2006-07-05 2009-03-09 인터뮨, 인크. New Inhibitors of Hepatitis C Virus Replication
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (en) 2008-09-11 2010-04-30 Enanta Pharm Inc HEPATITIS C SERINA PROTEASAS MACROCYCLIC INHIBITORS
EP2417134B1 (en) 2009-04-08 2017-05-17 Idenix Pharmaceuticals LLC. Macrocyclic serine protease inhibitors
US8703700B2 (en) * 2009-05-22 2014-04-22 Sequoia Pharmaceuticals, Inc. Bimacrocylic HCV NS3 protease inhibitors
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
JP2013518060A (en) 2010-01-25 2013-05-20 エナンタ ファーマシューティカルズ インコーポレイテッド Hepatitis C virus inhibitor
WO2012092409A2 (en) 2010-12-30 2012-07-05 Enanta Phararmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
CA2821340A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc. Phenanthridine macrocyclic hepatitis c serine protease inhibitors
TW201309690A (en) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SG11201502802PA (en) 2012-10-19 2015-05-28 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9310374B2 (en) 2012-11-16 2016-04-12 Redwood Bioscience, Inc. Hydrazinyl-indole compounds and methods for producing a conjugate
CN105164148A (en) 2013-03-07 2015-12-16 百时美施贵宝公司 Hepatitis c virus inhibitors
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
KR102783230B1 (en) 2015-11-09 2025-03-19 알.피.쉐러 테크놀러지즈 엘엘씨 Anti-CD22 antibody-maytansine conjugate and method of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601709B2 (en) * 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
AU2004211637C1 (en) * 2003-02-07 2010-08-19 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
US20040180815A1 (en) * 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors

Also Published As

Publication number Publication date
WO2008019303A2 (en) 2008-02-14
CO6020004A1 (en) 2009-03-31
WO2008019303A3 (en) 2008-10-30
ECSP077649A (en) 2008-03-26

Similar Documents

Publication Publication Date Title
PE20080539A1 (en) MACROCYCLIC PYRIDAZINONYLS AS SERINE PROTEASE INHIBITORS OF HEPATITIS C
PE20080992A1 (en) QUINOXALINYL MACROCYCLIC SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS
TW200639169A (en) Bicyclic heteroaryl derivatives for treating viruses
PE20080457A1 (en) MACROCYCLIC OXIMYL COMPOUNDS INHIBITORS OF HEPATITIS C PROTEASES
ATE526341T1 (en) MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS
TW200730478A (en) N-(6-membered aromatic ring)-amido anti-viral compounds
NO20080879L (en) HCV NS3 protease inhibitors
TW200720285A (en) Nucleoside compounds for treating viral infections
EA200701850A1 (en) CONNECTIONS OF TRICYCLIC NUCLEOSIDES (OPTIONS), PHARMACEUTICAL COMPOSITION ON THEIR BASIS AND METHOD OF TREATING OR PREVENTING VIRAL INFECTIONS IN MAMMALIANS
ATE528304T1 (en) COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA
PE20140015A1 (en) INHIBITORS OF MACROCYCLIC PROLINE-DERIVED HCV SERINE PROTEASES
CU23787B7 (en) MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION
PE20081532A1 (en) NOVEL COMPOUNDS
NO20092053L (en) HCV NS3 protease inhibitors
CY1107200T1 (en) SUSPITUS SUSPENSION UNITS C
PE20060837A1 (en) 3H-OXAZOLE AND 3H-THIAZOLE [4,5-d] PYRIMIDIN-2-ONA 3,5-DISUSTITUIDE AND 3,5,7-TRISUSTITUIDE COMPOUNDS AND PROPHARMACES OF THE SAME
WO2007070600A3 (en) N-(5-membered heteroaromatic ring)-amido anti-viral compounds
MA33209B1 (en) INHIBITORS OF HEPATITIS C VIRUS REPLICATION
PE20071322A1 (en) DERIVATIVES OF 2-MORPHOLINOPYRIMIDINE AS INHIBITORS OF PHOSPHATIDINOINOSITOL (PI) 3-KINASE
AR062224A1 (en) MACROCICLIC TETRAZOLILS AS SERINA PROTEASA NS3 INHIBITORS OF HEPATITIS C VIRUS AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM.
PE20081792A1 (en) SERINE PROTEASE INHIBITORS
TW200602064A (en) Nucleoside derivatives for treating hepatitis C virus infection
PE20070115A1 (en) DERIVATIVES OF [1,3,5] -TRIAZINE AS INHIBITORS OF ASPARTILE PROTEASES
PE20080072A1 (en) HETEROCYCLIC COMPOUNDS AS INHIBITORS OF SERINE PROTEASES
NO20091596L (en) Benzoylamino Heterocyclic Compounds as Glucokinase (GLK) Activators

Legal Events

Date Code Title Description
FC Refusal